Analyst consensus rating
Damora Therapeutics Analyst Rating: Strong Buy
DMRA is rated Strong Buy by 9 analysts with a $44.67 target. As of 2026-09-01.
Direct answer
Damora Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.67.
Forecast evidence checked September 1, 2026.
Get free Damora Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $28.18
- Average price target
- $44.67
- High price target
- $51.00
- Low price target
- $40.00
- Low target gap
- +41.9%
- Target upside
- +58.5%
- High target gap
- +81%
- Target range width
- 39%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Damora Therapeutics?
Damora Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $44.67.
How far are Damora Therapeutics's low and high targets from the recorded price?
The low target implies +41.9%, while the high target implies +81%.
How many analysts are included in Damora Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Damora Therapeutics's target upside or downside calculated?
The average target of $44.67 is divided by the recorded price of $28.18, then one is subtracted to produce +58.5%. This does not guarantee a future return.
When was Damora Therapeutics's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.